Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.

Scientific reports - 11 Jan 2021

Pinon Michele, De Nicolò Amedeo, Pizzol Antonio, Antonucci Miriam, D'Avolio Antonio, Serpe Loredana, Dell'Olio Dominic, Catalano Silvia, Tandoi Francesco, Romagnoli Renato, Canaparo Roberto, Calvo Pier Luigi

Abstract excerpt

Tacrolimus (TAC) pharmacokinetics is influenced by the donor CYP3A5 genotype and the age of pediatric liver recipients. However, an optimization of a genotype-based algorithm for determining TAC starting is needed to earlier achieve stable target levels. As the graft itself is responsible for its metabolism, the Graft-to-Recipient Weight Ratio (GRWR) might play a role in TAC dose requirements. A single-center...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Rejection

Share to Liver Transplantation

Share to Organ Size

Share to Postoperative Period

Share to Tacrolimus

Share to Tissue Donors

Source

Open in PubMed Open full text

Identifiers

PMID: 33432012
DOI: 10.1038/s41598-020-79574-7
PMCID: PMC7801660

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.PMID 33432012Read ↗

Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.Semantic proximity Read ↗

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver TransplantationSemantic proximity Read ↗

GRWR Correlates with the Metabolism of Tacrolimus After Pediatric Living Donor Liver Transplantation Accorrding to Donor CYP3A5 PolymorphismSemantic proximity Read ↗

The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.Semantic proximity Read ↗

CYP3A4/5 genotypes and age codetermine tacrolimus concentration and dosage in pediatric heart transplant recipients.Semantic proximity Read ↗

A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation.Semantic proximity Read ↗

GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism.Semantic proximity Read ↗

Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.Semantic proximity Read ↗

A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.Semantic proximity Read ↗

The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.Semantic proximity Read ↗

Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism.Semantic proximity Read ↗

Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.